Skip to Content
Merck
  • Latest advancements in the pharmacological treatment of binge eating disorder.

Latest advancements in the pharmacological treatment of binge eating disorder.

European review for medical and pharmacological sciences (2013-01-03)
D Marazziti, M Corsi, S Baroni, G Consoli, M Catena-Dell'Osso
ABSTRACT

Binge-eating disorder (BED) is a relatively new disorder characterized by binge eating without purging. The purpose of this article is to review the potential use of the recently proposed compounds for the treatment of BED. A medline of published articles from 1980 to December 2012 was carried out using the following keywords: BED and treatment, topiramate, zonisamide, ghrelin. The pharmacological treatment of BED is still heterogenous and poorly established, mainly for the lack of controlled studies in large samples of patients. The data on serotonin and norepinephrine reuptake inhibitors and on novel anticonvulsants seem quite promising in terms of efficacy and tolerability. In addition, the preliminary findings on the possibility of modulating appetite through the interference with the ghrelin system suggest new and intriguing ways of intervention in BED.

MATERIALS
Product Number
Brand
Product Description

Supelco
Zonisamide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Zonisamide sodium salt, ≥98% (HPLC), powder